Endothelin receptor antagonists as disease modifiers in systemic sclerosis

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 1, 2011, Pages 19-26

  Shetty, Nagalakshmi ^a   Derk, Chris T ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Ambrisentan; Bosentan; Endothelin receptor antagonists; Fibrosis; Scleroderma; Sitaxsentan; Systemic sclerosis

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; SITAXSENTAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; CUTANEOUS TELANGIECTASIA; DIGITAL ULCER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; FIBROSING ALVEOLITIS; HEART MUSCLE FIBROSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOPATHOGENESIS; INCIDENCE; INFARCTION; KIDNEY FIBROSIS; LUNG FIBROSIS; MALIGNANT HYPERTENSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCLERODERMA; SKIN FIBROSIS; SKIN ULCER; SLERODERMA RENAL CRISIS; STOMACH ANTRUM VASCULAR ECTASIA; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VASODILATATION;

EID: 79551625509     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811794352088     Document Type: Article

References (76)

1. LeRoy, E.C.; Black, C.; Fleischmajer, R.; Jablonska, S.; Krieg, T.; Medsger, T.A. Jr.; Rowell, N.; Wollheim, F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol., 1988, 15(2), 202-205.
2. Krieg, T.; Takehara, K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl. 3), iii14-18.
3. Grassegger, A.; Pohla-Gubo, G.; Frauscher, M.; Hintner, H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien. Med. Wochenschr., 2008; 158(1-2), 19-28.
4. Yamane, K.; Kashiwagi, H.; Suzuki, N.; Miyauchi, T.; Yanagisawa, M.; Goto, K.; Masaki, T. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum., 1991, 34(2), 243-244.
5. Galiè, N.; Manes, A.; Branzi, A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res., 2004, 61(2), 227-237.
6. La, M.; Reid, J.J. Endothelin-1 and the regulation of vascular tone. Clin. Exp. Pharmacol. Physiol., 1995, 22(5), 315-323.
7. Fagan, K.A.; McMurtry, I.F.; Rodman, D.M. Role of endothelin-1 in lung disease. Respir. Res., 2001, 2(2), 90-101.
8. Shimada, K.; Matsushita, Y.; Wakabayashi, K.; Takahashi, M.; Matsubara, A.; Iijima, Y.; Tanzawa, K. Cloning and functional expression of human endothelin-converting enzyme cDNA. Biochem. Biophys. Res. Commun., 1995, 207(2), 807-812.
9. Fernandez-Patron, C.; Zouki, C.; Whittal, R.; Chan, J.S.; Davidge, S.T.; Filep, J.G. Matrix metalloproteinases regulate neutrophilendothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J., 2001, 15(12), 2230-2240.
10. Shetty, S.S.; Okada, T.; Webb, R.L.; Del Grande, D.; Lappe, R.W. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem. Biophys. Res. Commun., 1993, 191(2), 459-464.
11. Abraham, D.J.; Vancheeswaran, R.; Dashwood, M.R.; Rajkumar, V.S.; Pantelides, P.; Xu, S.W.; du Bois, R.M.; Black, C.M. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol., 1997, 151(3), 831-841.
12. Bauer, M.; Wilkens, H.; Langer, F.; Schneider, S.O.; Lausberg, H.; Schäfers, H.J. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation, 2002, 105(9), 1034-1036.
13. Vancheeswaran, R.; Magoulas, T.; Efrat, G.; Wheeler-Jones, C.; Olsen, I.; Penny, R.; Black, C.M. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J. Rheumatol., 1994, 21(10), 1838-1844.
14. Shi-Wen, X.; Chen, Y.; Denton, C.P.; Eastwood, M.; Renzoni, E.A.; Bou-Gharios, G.; Pearson, J.D.; Dashwood, M.; du Bois, R.M.; Black, C.M.; Leask, A.; Abraham, D.J.Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac-phosphoinositide 3-kinase-Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell, 2004, 15(6), 2707-2719.
15. Shi-wen, X.; Kennedy, L.; Renzoni, E.A.; Bou-Gharios, G.; du Bois, R.M.; Black, C.M.; Denton, C.P.; Abraham, D.J.; Leask, A. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum., 2007; 56(12), 4189-4194.
16. Cambrey, A.D.; Harrison, N.K.; Dawes, K.E.; Southcott, A.M.; Black, C.M.; du Bois, R.M.; Laurent, G.J.; McAnulty, R.J. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell Mol. Biol., 1994, 11(4), 439-445.
17. Reichenberger, F.; Schauer, J.; Kellner, K.; Sack, U.; Stiehl, P.; Winkler, J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung, 2001, 179(3), 163-174.
18. Carpagnano, G.E.; Kharitonov, S.A.; Wells, A.U.; Pantelidis, P.; Du Bois, R.M.; Barnes, P.J. Increased vitronectin and endothelin-1 in the breath condensate of patients with fibrosing lung disease. Respiration, 2003, 70(2), 154-160.
19. Carpagnano, G.E.; Kharitonov, S.A.; Wells, A.U.; Pantelidis, P.; Du Bois, R.M.; Barnes, P.J. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann. Rheum. Dis., 1994, 53(8), 506-510.
20. Xu, S.; Denton, C.P.; Holmes, A.; Dashwood, M.R.; Abraham, D.J.; Black, C.M. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J. Cardiovasc. Pharmacol., 1998, 31(Suppl 1), S360-S363.
21. Denton, C.P.; Humbert, M.; Rubin, L.; Black, C.M. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheum. Dis., 2006, 65(10), 1336-1340.
22. Korn, J.H.; Mayes, M.; Matucci, C.M.; Rainisio, M.; Pope, J.; Hachulla, E.; Rich, E.; Carpentier, P.; Molitor, J.; Seibold, J.R.; Hsu, V.; Guillevin, L.; Chatterjee, S.; Peter, H.H.; Coppock, J.; Herrick, A.; Merkel, P.A.; Simms, R.; Denton, C.P.; Furst, D.; Nguyen, N.; Gaitonde, M.; Black, C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum., 2004, 50(12), 3985-3993.
23. Denton, C.P.; Black, C.M.; Abraham, D.J. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat. Clin. Pract. Rheumatol., 2006, 2(3), 134-144.
24. Denton, C.P.; Black, C.M. Scleroderma--clinical and pathological advances. Best Pract. Res. Clin. Rheumatol., 2004, 18(3), 271-290.
25. Lasky, J.A.; Brody, A.R. Interstitial fibrosis and growth factors. Environ. Health Perspect., 2000, 108(Suppl 4), 751-762.
26. Tomasek, J.J.; Gabbiani, G.; Hinz, B.; Chaponnier, C.; Brown, R.A. Myofibroblasts and mechanoregulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol., 2002, 3(5), 349-363.
27. Clements, P.J.; Lachenbruch, P.A.; Seibold, J.R.; Zee, B.; Steen, V.D.; Brennan, P.; Silman, A.J.; Allegar, N.; Varga, J.; Massa, M. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J. Rheumatol., 1993, 20(11), 1892-1896.
28. Furst, D.E.; Clements, P.J.; Steen, V.D; Medsger, T.A. Jr.; Masi, A.T.; D'Angelo, W.A.; Lachenbruch, P.A.; Grau, R.G.; Seibold. J.R. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J. Rheumatol., 1998, 25(1), 84-88.
29. Clements, P.J.; Hurwitz, E.L.; Wong, W.K.; Seibold, J.R.; Mayes, M.; White, B.; Wigley, F.; Weisman, M.; Barr, W.; Moreland, L.; Medsger, T.A. Jr.; Steen, V.D.; Martin, R.W.; Collier, D.; Weinstein, A.; Lally, E.; Varga, J.; Weiner, S.R.; Andrews, B.; Abeles, M.; Furst, D.E. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rhem., 2000, 43(11), 2445-2454.
30. Torres, J.E.; Sanchez, J.L. Histopathological differentiation between localized and systemic sclerosis. Am. J. Dermatopathol., 1998, 20(3), 242-245.
31. Jimenez, S.A.; Derk, C.T. Following the molecular pathways towards an understanding of the pathogenesis of systemic sclerosis. Ann. Intern. Med., 2004, 140(1), 37-50.
32. Xu, S.W.; Denton, C.P.; Dashwood, M.R.; Abraham, D.J.; Black, C.M. ET-1 regulation of ICAM-1 expression in normal and sclerodermal fibroblasts. J. Cardiovasc. Pharmocol., 1998, 31(Suppl 1), S545-S547.
33. Shi-Wen, X.; Renzoni, E.A.; Kennedy, L.; Howat, S.; Chen, Y.; Pearson, J.D.; Bou-Gharios, G.; Dashwood, M.R.; du Bois, R.M.; Black, C.M.; Denton, C.P.; Abraham, D.J.; Leask, A. Endogenous endothelin-1 signalling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol., 2007, 26(8), 625-632.
34. Alegre-Sancho, J.J.; Roman-Ivorra, J.A.; Chalmeta-Verdejo, C. Bosentan therapy for cutaneous fibrosis in systemic sclerosis. Curr. Med. Res. Opin., 2007, 23, 89-96.
35. Kuhn, A.; Haust, M.; Ruland, V.; Weber, R.; Verde, P.; Felder, G.; Ohmann, C.; Gensch, K.; Ruzicka, T. Effect of Bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, openlabel, non-comparative trial. Rheumatology (Oxford), 2010, 49(7), 1336-1345.
36. White B. Interstitial lung disease in scleroderma. Rheum. Dis. Clin. North Am., 2003, 29(2), 371-390.
37. Launay, D.; Remy-Jardin, M.; Michon-Pasturel, U.; Mastora, I.; Hachulla, E.; Lambert, M.; Delannoy, V.; Queyrel, V.; Duhamel, A.; Matran, R.; De Groote, P.; Hatron, P.Y. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J. Rheumatol., 2006, 33(9), 1789-1801.
38. Peacock, A.J.; Dawes, K.E.; Shock, A.; Gray, A.J.; Reeves, J.T.; Laurent, G.J. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am. J. Respire. Cell Mol. Biol., 1992, 7(5), 492-499.
39. Shi-Wen, X.; Denton, C.P.; Dashwood, M.R.; Holmes, A.M.; Bou-Gharios, G.; Pearson, J.D.; Black, C.M.; Abraham, D.J. Fibroblast matrix gene expression and connective tissue remodeling:role of endothelin-1. J. Invest. Dermatol., 2001, 116(3), 417-425
40. Hocher, B.; Schwarz, A.; Fagan, K.A.; Thöne-Reineke, C.; El-Hag, K.; Kusserow, H.; Elitok, S.; Bauer, C.; Neumayer, H.H.; Rodman, D.M.; Theuring, F. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol., 2000, 23(1), 19-26.
41. Giaid, A.; Yanagisawa, M.; Langleben, D.; Michel, R.P.; Levy, R.; Shennib, H.; Kimura, S.; Masaki, T.; Duguid, W.P.; Stewart, D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med., 1993, 328(24), 1732-1739.
42. Adamson, I.Y.; Bowden, D.H. The pathogenesis of bloemycin induced pulmonary fibrosis in mice. Am. J. Pathol., 1974, 77(2), 185-197.
43. Park, S.H.; Saleh, D.; Giaid, A.; Michel, R.P. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med., 1997, 156(2 Pt 1), 600-608.
44. Mutsaers, S.E.; Foster, M.L.; Chambers, R.C.; Laurent, G.J.; McAnulty, R.J. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am. J. Respir. Cell Mol. Biol., 1998, 18(5), 611-619.
45. Mutsaers, S.E.; Marshall, R.P.; Goldsack, N.R.; Laurent, G.J.; McAnulty, R.J. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm. Pharmacol. Ther., 1998, 11(2-3), 221-225.
46. Giaid, A.; Michel, R.P.; Stewart, D.J.; Sheppard, M.; Corrin, B.; Hamid, Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet, 1993, 341(8860), 1550-1554.
47. King, T.E. Jr.; Behr, J.; Brown, K.K.; du Bois, R.M.; Lancaster, L.; de Andrade, J.A.; Stähler, G.; Leconte, I.; Roux, S.; Raghu, G. BUILD-1: a randomized placebo controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2008, 177(1), 75-81.
48. Seibold, J.R.; Denton, C.P.; Furst, D.E.; Guillevin, L.; Rubin, L.J.; Wells, A.; Matucci, C.M.; Riemekasten, G.; Emery, P.; Chadha-Boreham, H.; Charef, P.; Roux, S.; Black, C.M. Randomized, Prospective, Placebo-Controlled Trial of Bosentan in Interstitial Lung Disease Secondary to Systemic Sclerosis. Arthritis Rheum., 2010, 62(7), 2101-2108.
49. Actelion;ClinicalTrials.gov.http://clinicaltrials.gov/ct2/show/NCT0 0631475? [Accessed on August 2, 2010].
50. Follansbee, W.P.; Curtiss, E.I.; Medsger, T.A. Jr.; Steen, V.D.; Uretsky, B.F.; Owens, G.R.; Rodnan, G.P. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N. Engl. J. Med., 1984, 310(3), 142-148.
51. Kahan, A.; Devaux, J.Y.; Amor, B.; Menkès, C.J.; Weber, S.; Nitenberg, A.; Venot, A.; Guérin, F.; Degeorges, M.; Roucayrol, J.C. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N. Engl. J. Med., 1986, 314(22), 1397-1402.
52. Candell-Riera, J.; Armadans-Gil, L.; Simeón, C.P.; Castell-Conesa, J.; Fonollosa-Pla, V.; García-del-Castillo, H.; Vaqué-Rafart, J.; Vilardell, M.; Soler-Soler, J. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum., 1996, 39(7), 1138-1145.
53. Allanore, Y.; Meune, C.; Vignaux, O.; Weber, S.; Legmann, P.; Kahan, A. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J. Rheumatol., 2006, 33(12), 2464-2469.
54. Kahaleh, M.B.; Sherer, G.K.; LeRoy, E.C. Endothelial injury in scleroderma. J. Exp. Med., 1979, 49(6), 1326-1335.
55. Cerinic, M.M.; Valentini, G.; Sorano, G.G.; D'Angelo, S.; Cuomo, G.; Fenu, L.; Generini, S.; Cinotti, S.; Morfini, M.; Pignone, A.; Guiducci, S.; Del Rosso, A.; Kalfin, R.; Das, D.; Marongiu, F. Blood coagulation, fibrinolysis and markers of endothelial dysfunction in systemic sclerosis. Semin. Arthritis Rheum., 2003, 32(5), 285-295.
56. Biondi, M.L.; Marasini, B.; Bassani, C.; Agastoni, A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N. Engl. J. Med., 1991, 324(16), 1139-1140.
57. Yamane, K.; Miyauchi, T.; Suzuki, N.; Yuhara, T.; Akama, T.; Suzuki, H.; Kashiwagi, H. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J. Rheumatol., 1992, 19(10), 1566-1571.
58. Flavahan, N.A.; Flavahan, S.; Mitra, S.; Chotani, M.A. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum. Dis. Clin. North Am., 2003, 29(2), 275-291.
59. Distler, O.; Distler, J.H.; Scheid, A.; Acker, T.; Hirth, A.; Rethage, J.; Michel, B.A.; Gay, R.E.; Müller-Ladner, U.; Matucci-Cerinic, M.; Plate, K.H.; Gassmann, M.; Gay, S. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ. Res., 2004, 95(1), 109-116.
60. Ferri, C.; Valentini, G.; Cozzi, F.; Sebastiani, M.; Michelassi, C.; La Montagna, G.; Bullo, A.; Cazzato, M.; Tirri, E.; Storino, F.; Giuggioli, D.; Cuomo, G.; Rosada, M.; Bombardieri, S.; Todesco, S.; Tirri, G. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore), 2002, 81(2), 139-153.
61. Matucci-Cerinic, M.; Denton, C.P.; Furst, D.E.; Mayes, M.D.; Hsu, V.M.; Carpentier, P.; Wigley, F.M.; Black, C.M.; Fessler, B.J.; Merkel, P.A.; Pope, J.E.; Sweiss, N.J.; Doyle, M.K.; Hellmich, B.; Medsger, T.A. Jr.; Morganti, A.; Kramer, F.; Korn, J.H.; Seibold, J.R. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis., 2010, [Epub ahead of print].
62. Humbert, M.; Cabane, J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford), 2003, 42(1), 191-193.
63. Snyder, M.J.; Jacobs, M.R.; Grau, R.G.; Wilkes, D.S.; Knox, K.S. Resolution of severe digital ulceration during a course of Bosentan therapy. Ann. Intern. Med., 2005; 142(9), 802-803.
64. Launay, D.; Diot, E.; Pasquier, E.; Mouthon, L.; Boullanger, N.; Fain, O.; Jego, P.; Carpentier, P.; Hatron, P.Y.; Hachulla, E. Bosentan for treatment of active digital ulcers in patients with SSc. Press. Med., 2006, 35(4), 587-592.
65. Tsifetaki, N.; Botzoris, V.; Alamanos, Y.; Argyriou, E.; Zioga, A.; Drosos, A.A. Bosentan for Digital Ulcers in patients with Systemic Sclerosis: A prospective 3-year follow-up study. J. Rheumatol., 2009, 36(7), 1550-1551.
66. Funauchi, M.; Kishimoto, K.; Shimazu, H.; Nagare, Y.; Hino, S.; Yano, T.; Kinoshita, K. Effects of bosentan on skin lesions: an observational study from a single center in Japan. Rheumatol. Int., 2009, 29(7), 769-775.
67. Ferreira, M.E. Schneinberg MA. Successful treatment with bosentan of non-digital skin ulcers in severe SSc. Ann. Rheum. Dis., 2008, 67(12), 1784-1785.
68. Trad, S.; Amoura, Z.; Beigelman, C.; Haroche, J.; Costedoat, N.; Boutin le, T.H.; Cacoub, P.; Frances, C.; Wechsler, B.; Grenier, P.; Piette, J.C. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum., 2006, 54(1), 184-191.
69. Rich, S.; Dantzker, D.R.; Ayres, S.M.; Bergofsky, E.H.; Brundage, B.H; Detre, K.M.; Fishman, A.P.; Goldring, R.M.; Groves, B.M.; Koerner, S.K. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med., 1987, 107(2), 216-223.
70. Stupi, A.M.; Steen, V.D.; Owens, G.R. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum., 1986, 29(4), 515-524.
71. Ungerer, R.G.; Tashkin, D.P.; Furst, D.; Clements, P.J.; Gong, H. Jr., Bein, M.; Smith, J.W.; Roberts, N.; Cabeen, W. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am. J. Med., 1983, 75(1), 65-74.
72. Mukerjee, D.; St George, D.; Coleiro, B.; Knight, C.; Denton, C.P.; Davar, J.; Black, C.M.; Coghlan, J.G. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis., 2003, 62(11), 1088-1093.
73. Hachulla, E.; Gressin, V.; Guillevin, L.; Carpentier, P.; Diot, E.; Sibilia, J.; Kahan, A.; Cabane, J.; Francès, C.; Launay, D.; Mouthon, L.; Allanore, Y.; Tiev, K.P.; Clerson, P.; de Groote, P.; Humbert, M. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum., 2005, 52(12), 3792-3800.
74. Koh, E.T.; Lee, P.; Gladman, D.D.; Abu-Shakra, M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. J. Rheumatol., 1996, 35(10), 989-993.
75. Kawut, S.M.; Taichman, D.B.; Archer-Chicko, C.L.; Palevsky, H.I.; Kimmel, S.E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest, 2003, 123(2), 344-350.
76. Williams, M.H.; Das, C.; Handler, C.E.; Akram, M.R.; Davar, J.; Denton, C.P.; Smith, C.J.; Black, C.M.; Coghlan, J.G. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart, 2006, 92(7), 926-932.